SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-NRX Pharmaceuticals Says FDA Denied Breakthrough Therapy Designation Request For Zyesami (Aviptadil)

reuters.com · 06/10/2022 22:53
BRIEF-NRX Pharmaceuticals Says FDA Denied Breakthrough Therapy Designation Request For Zyesami (Aviptadil)

- NRX Pharmaceuticals Inc NRXP:

  • NRX PHARMACEUTICALS PROVIDES UPDATE ON BREAKTHROUGH THERAPY DESIGNATION (BTD) REQUEST FOR ZYESAMI® (AVIPTADIL)

  • NRX PHARMACEUTICALS- U.S. FOOD AND DRUG ADMINISTRATION (FDA) DENIED THE BREAKTHROUGH THERAPY DESIGNATION (BTD) REQUEST FOR ZYESAMI® (AVIPTADIL)

Source text for Eikon: ID:nPn4yfZr3a

Further company coverage: NRXP


((Reuters.briefs@thomsonreuters.com;))